No Data
No Data
Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024
Ribomic 9-Mos Parent Loss Y740.00M Vs Loss Y802.00M
Ribomic Sees FY Loss Y1.40B
Volume change rate ranking (9 o'clock hour) - Data SEC, Nichicon, etc. are ranked.
In the volume change rate ranking, comparing the average volume over the last five days with the volume on the day of distribution allows insight into market participants' interests, such as trends in stock selection. ■ Top volume change rates [As of February 7, 9:32] (Compared to the average volume over the last five days) Stock Code Stock Name Volume Average Volume over 5 Days Volume Change Rate Stock Price Change Rate <3666> Technos JPN 2641000 107185.08 341.89% 0.015% <4591> Rebo
Soft market conditions, profit-taking sell-offs are prevailing [Emerging Markets individual stock Global Strategy].
[Emerging Markets Individual Stock Global Strategy] Today's emerging markets are expected to show a sluggish performance. In the US stock market yesterday, October 6th, the Dow Inc decreased by 125.65 points (-0.28%) to 44,747.63 dollars, reversing after three days. Expectations for additional interest rate cuts and strong earnings from some major companies supported stock prices, but rising caution ahead of employment statistics led to a decline in the Dow. On the other hand, the Nasdaq saw strong buying activity in high-tech stocks due to expectations surrounding Artificial Intelligence (AI), which expanded gains towards the end of the day. Today's emerging
Lear Gate, Ribomic and others.
<2385> The subsidiary NRL Pharma of General Medical Research Institute has obtained a patent. <4591> Announcement regarding the success of the low-dose group in the Phase II clinical trial of the drug for treating achondroplasia (umedaptanib pegol) at the Ribomic Fusion Conference 2025. <4592> The second manufacturing results related to the approval conditions for the shipping of Sun Bio Acugo for intracranial transplantation. <4891> Regarding TIM's TMS-007 (JX10).